Recent Finacing
Recent Raise
Annexon develops antibody therapeutics that inhibit C1q and the classical complement pathway, advancing clinical and preclinical programs (ANX005, ANX007) for autoimmune, neurodegenerative, and ophthalmic diseases.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
